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Background: Genetic variants may predispose humans to elevated risk of common metabolic morbidities such
as obesity and Type 2 Diabetes (T2D). Some of these variants have also been shown to influence elite athletic
performance and the response to exercise training. We compared the genotype distribution of five genetic
Single Nucleotide Polymorphisms (SNPs) known to be associated with obesity and obesity co-morbidities
(IGF2BP2 rs4402960, LPL rs320, LPL rs328, KCJN rs5219, and MTHFR rs1801133) between athletes (all male, n = 461;
endurance athletes n = 254, sprint/power athletes n = 207), and controls (all male, n = 544) in Polish and Russian
samples. We also examined the association between these SNPs and the athletes’ competition level (‘elite’ and
‘national’ level). Genotypes were analysed by Single-Base Extension and Real-Time PCR. Multinomial logistic
regression analyses were conducted to assess the association between genotypes and athletic status/competition
level.
Results: IGF2BP2 rs4402960 and LPL rs320 were significantly associated with athletic status; sprint/power athletes
were twice more likely to have the IGF2BP2 rs4402960 risk (T) allele compared to endurance athletes (OR = 2.11,
95% CI = 1.03-4.30, P <0.041), and non-athletic controls were significantly less likely to have the T allele compared
to sprint/power athletes (OR = 0.62, 95% CI =0.43-0.89, P <0.0009). The control group was significantly more likely
to have the LPL rs320 risk (G) allele compared to endurance athletes (OR = 1.26, 95% CI = 1.05-1.52, P <0.013).
Hence, endurance athletes were the “protected” group being significantly (p < 0.05) less likely to have the risk
allele compared to sprint/power athletes (IGF2BP2 rs4402960) and significantly (p < 0.05) less likely to have the risk
allele compared to controls (LPL rs320). The other 3 SNPs did not show significant differences between the study
groups.
Conclusions: Male endurance athletes are less likely to have the metabolic risk alleles of IGF2BP2 rs4402960 and
LPL rs320, compared to sprint/power athletes and controls, respectively. These results suggest that some SNPs
across the human genome have a dual effect and may predispose endurance athletes to reduced risk of
developing metabolic morbidities, whereas sprint/power athletes might be predisposed to elevated risk.
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Complex metabolic diseases such as Obesity and Type 2
Diabetes (2TD) and physical activity levels have long
been recognised as being closely-related. For instance, it
has been shown that elite athletes or former elite ath-
letes tend to have longer life expectancies, and lower
risks of complex metabolic diseases such as obesity and
T2D, than matched sedentary controls [1-3]. Genetic
factors seem to play a role in elite athlete development,
on one hand [4,5], and the predisposing for complex
metabolic diseases, on the other hand [6]. Recently, we
[6] and others [7,8] hypothesised that genetic Single Nu-
cleotide Polymorphisms (SNPs), including SNPs identi-
fied in Genome Wide Association Studies (GWAS) that
have been associated with increased risk for complex
metabolic diseases, would also be candidates to influence
athletic performance/physical activity levels.
The A/T polymorphism (rs9939609) in the fat mass and
obesity associated (FTO) gene, was discovered in two sep-
arate GWAS [9,10], and is an example of specific variant
associated with obesity, 2TD, and physical activity levels.
Recent meta-analysis combining data from adults and
children, and an adolescent population (overall 54 studies
of n = 218,166 and n = 19,268, respectively) have shown
that physically active people with the FTO risk allele
are 30% less likely to be obese compared to their in-
active counterparts [11]. Visfatin, a recently discovered
adipokine that contributes to glucose and obesity-
related conditions, is another gene that potentially in-
fluences both exercise-related phenotypes and complex
metabolic diseases. rs4730153 within the Visfatin was as-
sociated with aerobic exercise training-induced changes in
glucose and obesity-related phenotypes [12]. The peroxi-
some proliferator-activated receptor gamma coactivator1α
(PPARGC1A) Gly482Ser SNP was also associated with in-
creased risk of obesity and type 2 diabetes [13] on one
hand, and with elite athletic performance [14-17], on the
other hand.
The outcomes of the abovementioned studies assist
with understanding the genomic link between complex
metabolic diseases and athletic performance; however
the widely accepted hypothesis is that there are likely to
be many other uncovered variants with dual effects. In
that sense, elite athletes represent the end point of the
human physical activity continuum with a “rare” and
distinguished phenotype, and hence are an excellent
model to study.
Potential obesity and T2D-related genetic variants
that may influence athletic performance as well are lo-
cated in the IGF2BP2, LPL, KCJN, and MTHFR genes.
IGF2BP2 rs4402960 G > T variant is associated with
predisposition to T2D and obesity. GWAS studies have
indicated that the risk allele for T2D and obesity is the
T allele. Animal model and human studies implicatethis variant with reduced beta-cell function, insulin se-
cretion and sensitivity and with raised fasting glucose
levels [18-20]. Importantly, recent studies suggest a po-
tential role for IGF2BP2 in skeletal muscle cell prolifer-
ation and differentiation [21]. LPL rs320 and rs328
SNPs have been associated with plasma lipids levels,
through the protein’s role in the uptake of Free Fatty Acids
(FFA) from the plasma to tissues, including muscle cells
[22-24]. Thus, it has been hypothesised that these SNPs
may alter the availability of FFA to muscle cells and to the
utilization of fat by muscles. The obesity risk allele/geno-
type for both rs320 and rs328 are G allele and the GG
genotype. KCNJ11 is an ATP-sensitive K+ (KATP) chan-
nel, which couples cell metabolism with membrane excit-
ability in various cell types, including muscle cells. The
protein’s known function is mainly related to diabetes
phenotypes [25]. However, it was also found to be associ-
ation with impaired exercise stress response in several
models. The E23K SNP at codon 23 of the KCNJ11 gene
(rs5219) results in substitution of glutamic acid to lysine,
and may cause modest reductions in ATP sensitivity,
which could influence muscle response to exercise. The
metabolic risk allele/genotype in rs5219 is T/TT. MTHFR
is a key enzyme in one carbon cycle. MTHFR C677T SNP
results in elevated plasma homocysteine, which has been
linked to reduced mobility and muscle functioning in the
elderly (women) and has been associated with T2D. The
risk allele/genotype in rs1801133 is T/TT [26,27].
Therefore, we studied the association between these
five genetic variants associated with both obesity and
obesity co-morbidities (IGF2BP2 rs4402960, LPL rs320,
LPL rs328, KCJN rs5219, and MTHFR rs1801133) and
elite athletic status in a relatively-large cohort (n = 929,
from Poland and Russia) of sprint/power and endurance
athletes. We also examined the association between
these variants and athletic status according to the ath-
letes’ level of competition (‘elite’ and ‘national’ level). We
hypothesised that the obesity and/or co-morbidities risk
allele/genotype in each of these variants would be under-
represented in elite athletes compared to controls.
Methods
The study was approved by the Pomeranian Medical
University Ethics Committee, Poland, and the Ural State
University of Physical Culture, Russia, and written in-
formed consent was obtained from each participant. The
study complied with the guidelines set out in the Declar-
ation of Helsinki and the ethics policy of the Szczecin
University [28].
Participants
A total of 929 male participants from Russia (n = 281)
and Poland (n = 648) were involved in the study. The
Russian participants included 177 athletes (mean
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trols (mean age = 31.2, SD = 10.4). The Polish participants
were 208 athletes (mean age = 28.6, SD = 6.2) and 440 un-
related sedentary controls (mean age = 22.4, SD = 2.5). All
athletes were ranked in the top 10 nationally in their sport
discipline and grouped as being either ‘elite-level’ or ‘na-
tional-level’ based on their best personal performance.
Those in the elite group had participated in international
competitions such as World and European Champion-
ships, and/or Olympic Games, whereas those in the
national-level group had participated in national competi-
tions only. Athletes were further classified as endurance
(events requiring predominantly aerobic energy produc-
tion including long distance and duration events or
sprint/power athletes (events requiring predominantly an-
aerobic energy production).
Russian athletes
This group included 70 (elite n = 10; 14%) endurance
athletes and 107 (elite n = 44; 41%) sprint/power ath-
letes. Athletes in classified as endurance athletes in-
cluded cross country skiers (n = 38), marathon runners
(n = 2), rowers (n = 13), 1500-5000 m runners (n = 4),
5000/10 000 m long distance skaters (n = 6), 3000 m
steeple chase (n = 1), 1500 m swimmers (n = 2) and
walkers (n = 4). Athletes classified as sprint/power ath-
letes came from sports including ski-cross/ alpine ski-
ing (n = 2), discus throw (n = 1), Greco-roman wrestling
(n = 10), pole vault (n = 1), 200 m sprint (n = 2), 100 m
sprint (n = 10), 400 m sprint (n = 1), 500 m shortTable 1 Genotype frequency distributions for IGFBP2 rs44029
Polish (n = 648)
Endurance Sprint/Power Co
All (N) 108 100 44
TT 10 (9%) 16 (16%) 42
GT 47 (44%) 40 (40%) 16
GG 51 (47%) 44 (44%) 23
MAF 0.31 0.36 0.2
HWE-P value 0.987 0.419 0.2
Elite (N) 65 64 -
TT 4 (6%) 14 (22%)
GT 28 (43%) 20 (31%)
GG 33 (51%) 30 (47%)
MAF 0.28 0.38
National Level (N) 43 36
TT 6 (14%) 2 (6%)
GT 19 (44%) 20 (56%)
GG 18 (42%) 14 (39%)
MAF 0.36 0.33
Note: TT is identified as the risk genotype.distance skating (n = 23), 50/100 m short distance
swimming (n = 8), and power lifters (n = 49).
Polish athletes
This group included 108 (elite n = 65; 60%) endurance
athletes and 100 (elite n = 64; 64%) sprint/power ath-
letes. Athletes classified as endurance athletes in-
cluded canoeists (n = 10), cross country skiers (n = 2),
cyclists (n = 14), 10 00 m/marathon runners (n = 25),
rowers (n = 41), 1500 m swimmers (n = 10), and triath-
letes (n = 6). The sprint/power athletes included 100/
200 m runners (n = 34), archers (n = 4), weight/ power
lifters (n = 42), high jumpers (n = 1), javelin throwers
(n = 1), long jumpers (n = 4), vaulters (n = 3), shooters
(n = 1), shot putters (n = 5), 500 m short-distance
skaters (n = 1) sky jumpers (n = 2) and 50/100 m swim-
mers (n = 2).
Genotyping
In the Polish cohort, Genomic DNA was isolated from
buccal epithelium using GenElute Mammalian Genomic
DNA Miniprep Kit (Sigma, Hamburg, Germany) accord-
ing to the manufacturer’s instructions. In the Russian co-
hort, Genomic DNA was isolated from buccal epithelium
or peripheral blood, during the years 2011-2013, using the
Diatom™ DNA Prep kit (Cat. # D 1025, IsoGene Lab
Ltd, Russia). Genotyping was performed as previously
described [29]. In the Russian cohort, genotyping of
four SNPs (IGFBP2 rs4402960, KCJN11 rs5219, LPL
rs320 and rs328) was performed by Single-Base60
Russian (n = 281)
ntrol Endurance Sprint/Power Control
0 70 107 104
(10%) 4 (6%) 13(12%) 11 (11%)
3 (37%) 37 (53%) 58 (54%) 39 (38%)
5 (53%) 29 (41%) 36 (34%) 54 (52%)
8 0.32 0.39 0.29
23 0.208 0.368 0.623
10 44 -
2 (20%) 7 (16%)
5 (50%) 22 (50%)
3 (30%) 15 (34%)
0.45 0.41
60 63 -
2 (3%) 6 (10%)
32 (53%) 36 (57%)
26 (43%) 21 (33%)
0.30 0.38
Table 2 Genotype frequency distributions for LPL rs320
Polish (n = 648) Russian (n = 281)
Endurance Sprint/Power Control Endurance Sprint/Power Control
All (N) 108 100 440 70 107 104
GG 8 (7%) 5 (5%) 21 (5%) 4 (6%) 13 (12%) 8 (8%)
GT 35 (32%) 46 (46%) 196 (45%) 26 (37%) 37 (35%) 48 (46%)
TT 65 (60%) 49 (49%) 223 (51%) 40 (57%) 57 (53%) 48 (46%)
MAF 0.24 0.28 0.27 0.24 0.29 0.31
HWE-P value 0.573 0.370 0.026 0.996 0.222 0.697
Elite (N) 65 64 - 10 44 -
GG 3 (5%) 4 (6%) 0 6 (14%)
GT 22 (33%) 30 (47%) 6 (60%) 12 (27%)
TT 40 (62%) 30 (47%) 4 (40%) 26 (59%)
MAF 0.22 0.30 0.30 0.27
National Level (N) 43 36 60 63 -
GG 5 (12%) 1 (3%) 4 (7%) 6 (10%)
GT 13 (30%) 16 (44%) 20 (33%) 29 (46%)
TT 25 (58%) 19 (53%) 36 (60%) 28 (44%)
MAF 0.27 0.25 0.23 0.33
Note: GG is identified as the risk genotype.
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each SNP was obtained from the Genome Reference
Consortium Human genome build 37 assembly from
the Ensembl Project (www.ensembl.org). The Primer3-
web software v. 4.0.0 (http://bioinfo.ut.ee/primer3) was
used for designing the PCR primers. Genotyping of theTable 3 Genotype distributions for LPL rs328
Polish (n = 648)
Endurance Sprint/Power Co
All (N) 108 100 44
GG 1(1%) 1 (1%) 6
GC 14 (13%) 17 (17%) 75
CC 93 (85%) 82 (82%) 35
MAF 0.07 0.10 0.1
HWE-P value 0.849 0.994 0.6
Elite (N) 65 64 -
GG 0 0
GC 7 (11%) 10 (16%)
CC 58 (89%) 54 (84%)
MAF 0.05 0.08
National Level (N) 43 36
GG 1 (2%) 1 (1%)
GC 7 (16%) 7 (19%)
CC 35 (81%) 28 (80%)
MAF 0.10 0.13
Note: GG is identified as the risk genotype.MTHFR rs1801133 polymorphism was performed by
using a TaqMan® SNP Genotyping Assay with a StepOne™
Real-Time PCR System (Applied Biosystems, Foster city,
CA, USA). The assay ID was C___1202883_20. The re-
sults were analysed by using TaqMan® Genotyper Software
(Applied Biosystem). K562 DNA High Molecular WeightRussian (n = 281)
ntrol Endurance Sprint/Power Control
0 70 107 104
(1%) 0 0 0
(17%) 8 (11%) 13 (12%) 16 (15%)
9 (82%) 62 (89%) 94 (88%) 88 (85%)
0 0.94 0.94 0.92
61 0.879 0.799 0.697
10 44 -
0 0
1 (10%) 10 (23%)
9 (90%) 34 (77%)
0.95 0.88
60 63 -
0 0
7 (23%) 3 (5%)
53 (77%) 60 (95%)
0.94 0.98
Table 4 Genotype frequency distributions for KCJN rs5219
Polish (n = 648) Russian (n = 281)
Endurance Sprint/Power Control Endurance Sprint/Power Control
All (N) 108 100 440 70 107 104
TT 14 (13%) 12 (12%) 60 (14%) 11 (16%) 13 (12%) 13 (13%)
CT 44 (41%) 50 (50%) 178 (40%) 26 (37%) 46 (42%) 49 (47%)
CC 50 (46%) 38 (38%) 202 (46%) 33 (47%) 49 (46%) 42 (40%)
MAF 0.33 0.37 0.33 0.34 0.336 0.36
HWE-P value 0.687 0.769 0.127 0.339 0.907 0.976
Elite (N) 65 64 - 10 44 -
TT 7 (11%) 6 (9%) 2 (20%) 7 (16%)
CT 25 (37%) 32 (50%) 3 (30%) 17 (39%)
CC 33 (51%) 26 (41%) 5 (50%) 20 (45%)
MAF 0.30 0.34 0.35 0.35
National Level (N) 43 36 60 63 -
TT 7 (16%) 6 (17%) 9 (15%) 6 (10%)
CT 19 (44%) 18 (50%) 23 (38%) 29 (46%)
CC 17 (40%) 12 (33%) 28 (47%) 28 (44%)
MAF 0.38 0.42 0.34 0.33
Note: TT is identified as the risk genotype.
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served as a positive control sample. Genetic profile of the
K562 DNA was as follow: IGFBP2 rs4402960 – G/G,
KCJN11 rs5219 – C/T, LPL rs320 – G/G, LPL rs328 – G/
C, and MTHFR rs1801133 – G/G.Table 5 Genotype frequency distributions for MTHFR rs18011
Polish (n = 648)
Endurance Sprint/Power Co
All (N) 108 100 44
TT 12 (11%) 9 (9%) 33
CT 43 (40%) 40 (40%) 18
CC 53 (49%) 51 (51%) 22
MAF 0.31 0.29 0.2
HWE-P value 0.770 0.960 0.7
Elite (N) 65 64 -
TT 11 (17%) 9 (14%)
CT 24 (37%) 25 (39%)
CC 30 (46%) 30 (47%)
MAF 0.35 0.34
National Level (N) 43 36 -
TT 1 (2%) 0
CT 19 (44%) 15 (42%)
CC 23 (53%) 21 (58%)
MAF 0.24 0.21
Note: TT is identified as the risk genotype.In the Polish cohort, all samples were genotyped in du-
plicate using allelic discrimination assays with Taqman®
probes (Applied Biosystems, Carlsbad, California, USA)
on a CFX96 Touch™ Real-Time PCR Detection System
(Bio-Rad, Hercules, California, USA). To discriminate33
Russian (n = 281)
ntrol Endurance Sprint/Power Control
0 70 107 104
(8%) 4 (6%) 11 (10%) 9 (9%)
6 (42%) 30 (43%) 52 (49%) 38 (37%)
1 (50%) 36 (51%) 44 (41%) 57 (55%)
9 0.27 0.35 0.27
72 0.78 0.745 0.767
10 44 -
2 (20%) 4 (9%)
5 (50%) 25 (57%)
3 (30%) 15 (34%)
0.45 0.38
60 63 -
2 (3%) 7 (11%)
25 (42%) 27 (43%)
33 (55%) 29 (46%)
0.24 0.33
Table 6 Ratios of genotype distributions according to athlete type for IGFBP2 rs4402960
Sport type GG (ref) GT TT TT (GT&GG ref) TT & GT (GG ref)
OR OR CI p OR CI p OR CI p OR CI p
Control vs. Sprint/Power 1 0.62 0.43-0.89 0.009 0.51 0.30-0.88 0.016 0.65 0.39-1.08 0.094 0.59 0.42-0.84 0.003
Sprint/Power vs. Endurance 1 1.10 0.71-1.70 0.661 2.11 1.03-4.30 0.041 2.00 1.01-3.95 0.045 1.24 0.83-1.88 0.298
Control vs. Endurance 1 0.83 0.69-0.99 0.041 1.02 0.74-1.41 0.887 1.11 0.82-1.53 0.487 0.86 0.72-1.02 0.086
Note: OR: Odds Ratio; CI: Confidence intervals; p: 2 tailed p value. Significance is assumed when p < 0.05.
IGFBP2 rs4402960.
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TaqMan® Pre-Designed SNP Genotyping Assays were
used (assay IDs: C___2165199_10, C___1843003_10,
C____901792_1_, C__11654065_10, C___1202883_20 re-
spectively), including appropriate primers and fluores-
cently labeled (FAM and VIC) MGB™ probes to detect the
alleles.
Genotyping reliability across two laboratories
As previously described [29] genotyping was performed
in duplicate in the same Laboratory for accuracy. Two
independent investigators have called the genotyping
score in each laboratory-100% of the genotypes could
be called. For the purpose of results reliability across
two laboratories in two different countries (Russia and
Poland), different DNA samples (one for each SNP,
positive or negative controls) were shipped from Russia
to Poland and were genotyped by TaqMan assays. The
results of the genotyping were in 100% agreement
across the two laboratories.
Statistical analysis
Chi squared tests were used to test for the presence of
Hardy-Weinberg equilibrium (HWE). HWE was tested
separately for each SNP. Genotype frequencies were
compared according to athletic status (i.e. controls, endur-
ance, or sprint/power athlete) using Fisher’s exact test.
Multinomial logistic regression analyses were conducted
to assess the association between genotype and athletic
status/competition level. Nationality was adjusted for in
the first stage of analysis as there were nationality distribu-
tion differences in each athletic status groups and the con-
trol group. The homozygous non-risk allele genotype
was chosen as the reference genotype for each analysis,
with comparisons made to the heterozygous genotype
and the homozygous risk allele genotype (co-dominantTable 7 Ratios of genotype distributions according to athlete
Sport type TT (ref) GT GG
OR OR CI p OR
Control vs. Sprint/Power 1 1.13 0.79-1.61 0.499 0.79
Sprint/Power vs. Endurance 1 1.37 0.89-2.11 0.152 1.42
Control vs. Endurance 1 1.26 1.05-1.52 0.013 1.00
Note: OR: Odds Ratio; CI: Confidence intervals; p: 2 tailed p value. Significance is assmodels). Additional comparisons were made to assess
the dominant and recessive models, as described in our
work [30]. Significance between these planned compari-
sons was accepted when p ≤ 0.05. Odds ratios with 95%
confidence intervals were also calculated for estimation
of the risk effect.Results
Genotype frequencies distribution for IGFBP2 rs440
2960, LPL rs320, LPL rs328, KCJN rs5219, and MTHFR
rs1801133 amongst all participants is presented in
Tables 1, 2, 3, 4, and 5. In the pooled cohort of Russian
and Polish controls, genotype distributions for each of
the five SNPs was in agreement with HWE (p-value >
0.05). In the Polish cohort LPL rs320 deviated from
HWE (P = 0.026), however LPL rs320 was in agreement
with HWE in the Russian cohort (p = 0.7) (Table 2).
The analyses for all the SNPs was performed on the
pooled cohort, hence the HWE deviation in the Polish
cohort had no effect on the results.
IGF2BP2 rs4402960 was significantly associated with
athletic status (Table 6). The control participants were
less likely than sprint/power athletes to have the TT
(increased risk) genotype compared to GG genotype
(OR: 0.62 [0.43-0.89]; p = 0.009), and TT and GT com-
bined (OR: 0.59 [0.42- 0.84]; p = 0.003). The sprint/power
athletes were more likely than endurance to be TT com-
pared to GG (OR: 2.11 [1.01-3.95]; p = 0.041), and GT and
TT combined (OR: 2.00 [1.01- 3.95]; p = 0.045).
LPL rs320 was also significantly associated with ath-
letic status. Table 7 shows that the control group is
more likely than the endurance athletes to have the
GT genotype compared to TT genotype (OR: 1.26
[1.05-1.52]; p = 0.013). Controls are also more likely
than endurance to have the risk-related GG&GTtype for LPL rs320
GG (GT& TT ref) GG & GT (TT ref)
CI p OR CI p OR CI p
0.40-1.55 0.494 0.75 0.39-1.44 0.384 1.07 0.77-1.51 0.681
0.65-3.11 0.386 1.25 0.58-2.69 0.570 1.38 0.92-2.07 0.124
0.69-1.44 0.996 0.91 0.63-1.29 0.510 1.22 1.03-1.46 0.024
umed when p < 0.05.
Table 8 Ratios of genotype distributions according to athlete type for LPL rs328
Sport type CC (ref) GC GG GG (GC&CC ref) GG & GC (CC ref)
OR OR CI p OR CI p OR CI p OR CI p
Control vs. Sprint/Power 1 1.22 0.59-2.52 0.594 1.17 0.49-2.80 0.728 0.97 0.55-1.71 0.924 1.21 0.59-2.49 0.602
Sprint/Power vs. Endurance 1 1.09 0.45-2.65 0.858 0.79 0.26-2.44 0.686 0.74 0.35-1.55 0.419 1.06 0.44-2.56 0.904
Control vs. Endurance 1 1.14 0.76-1.72 0.518 0.96 0.59-1.55 0.957 0.85 0.63-1.14 0.270 1.11 0.75-1.65 0.605
Note: OR: Odds Ratio; CI: Confidence intervals; p: 2 tailed p value. Significance is assumed when p < 0.05.
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[1.03-1.46]; p = 0.024).
There were no differences between the studied groups
and the control group across LPL rs328, KCJN rs5219,
and MTHFR rs1801133 genotypes (Tables 8, 9 and 10).
Furthermore, no significantly greater/lesser odds ratios
were observed for any of the genotypes in either compe-
tition level.
Finally, Tables 1, 2, 3, 4, and 5 show the percentage of
genotypes present in elite-level and national-level athletes
according to nationality and athletic status. No significant
genotype differences were observed between elite-level
and national-level athletes in all SNP and across national-
ities (all p > 0.05).
Discussion
We studied the association between five obesity and co-
morbidities-related genetic variants (IGF2BP2 rs4402960,
LPL rs320, LPL rs328, KCJN rs5219, and MTHFR
rs1801133) and athletic status in a well-defined (athletic
level, ethnicity, gender) athletic population. We found a
significant association between IGF2BP2 rs4402960 and
LPL rs320 and athletic status; endurance athletes are less
likely to have the metabolic risk IGF2BP2 T and LPL
rs320 G alleles compared with sprint/power athletes
and controls, respectively. These results suggest that male
endurance athletes might be genetically predisposed to-
ward a reduced risk of developing metabolic morbidities,
compared with sprint/power athletes and the general
population.
Previous studies have demonstrated that genetic vari-
ants associated with predisposition to obesity are also as-
sociated with responsiveness to exercise training [31-36].Table 9 Ratios of genotype distributions according to athlete
Sport type CC (ref) TC TT
OR OR CI p OR
Control vs. Sprint/Power 1 0.85 0.59-1.22 0.371 1.02
Sprint/Power vs. Endurance 1 1.36 0.88-2.11 0.165 0.96
Control vs. Endurance 1 1.07 0.89-1.29 0.498 1.01
Note: OR: Odds Ratio; CI: Confidence intervals; p: 2 tailed p value. Significance is assOnly a handful of variants, however, were replicated in
multiple cohorts mainly due to variability in exercise
training level, different ethnicity, gender, age, and cohorts
with different metabolic states. To overcome some of the
past studies challenges, including variability in physical ac-
tivity status, different ethnicity and gender, we recruited a
relatively- large cohort of Caucasians athletes with a well-
defined athletic phenotype.
IGF2BP2, also referred to as IMP2, belongs to a mRNA-
binding protein family involved in the development and
stimulation of insulin action. The IGF binding protein
family plays a role in modulation of IGF2 translation in a
tissue-specific and developmental manner [37,38]. Several
GWAS have found that carriers of the minor alleles in
SNPs rs1470579 and rs4402960 have moderately increased
risk for T2D. This association was confirmed across differ-
ent ethnicities and populations [37-46]. Furthermore, a re-
cent meta-analysis of 48 independent studies confirmed
this association in European, East Asian and South Asian
populations [47].
The intron 2 G > T substitution in the IGF2BP2 rs440
2960 is particularly interesting and has attracted the
most attention in obesity and T2D studies. The SNP is
located in the second, large IGF2BP2 intron; thus, it is
not yet clear how it generates its effect, whether dir-
ectly through regulatory effects or indirectly through
other genes. However, in the context of T2D, animal
model and human studies implicate a role for this vari-
ant in beta-cell function, insulin secretion and sensitiv-
ity, and with elevated fasting glucose levels [18-20].
Importantly, recent studies suggest a potential role for
IGF2BP2 protein in skeletal muscle cell proliferation
and differentiation [21]. In the present study we havetype for KCJN rs5219
TT (TC&CC ref) TT & TC (CC ref)
CI p OR CI p OR CI p
0.59-1.76 0.947 1.11 0.66-1.85 0.696 0.88 0.63-1.36 0.477
0.51-1.82 0.911 1.26 0.84-1.89 0.274 0.83 0.46-1.51 0.538
0.77-1.31 0.968 0.96 0.76-1.25 0.845 1.05 0.88-1.25 0.575
umed when p < 0.05.
Table 10 Ratios of genotype distributions according to athlete type for MTHFR rs1801133
Sport type AA (ref) GA GG GG (GA& AA ref) GG & GA (AA ref)
OR OR CI p OR CI p OR CI p OR CI p
Control vs. Sprint/Power 1 1.11 0.59-2.06 0.753 1.32 0.71-2.45 0.374 1.22 0.87-1.71 0.256 1.22 0.67-2.20 0.519
Sprint/Power vs. Endurance 1 0.97 0.47-2.01 0.932 0.84 0.41-1.74 0.647 0.87 0.58-1.30 0.488 0.90 0.45-1.81 0.768
Control vs. Endurance 1 1.09 0.79-1.50 0.610 1.11 0.81-1.53 0.508 1.10 0.81-1.50 0.536 1.04 0.87-1.23 0.670
Note: OR: Odds Ratio; CI: Confidence intervals; p: 2 tailed p value. Significance is assumed when p < 0.05.
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have the metabolic risk alleles of IGF2BP2 compared
to sprint/power athletes who are twice as much likely
to have the metabolic risk allele (homozygote) com-
pared to endurance athletes.
An additional finding in the present study is that en-
durance athletes are less likely to have the metabolic
risk, G allele, of LPL rs320, compared with controls. LPL
plays a pivotal role in lipid metabolism by hydrolysing
triglyceride -rich lipoproteins. Dysfunction of LPL pro-
tein increased the susceptibility for developing several
common diseases, including atherosclerosis and obesity
[22,47-50]. LPL rs320 or HindIII (intron 8) is a common
variant in the LPL gene that has been associated with
plasma lipid profile [22,24,51-54]. Although a large num-
ber of variants have been identified in the LPL gene,
rs320 is of particular interest because of its common oc-
currence in many populations. Due to LPL rs320′s loca-
tion within an intron, it was not initially considered
functional but rather in linkage disequilibrium with a
putative functional variant, such as LPL rs328. However,
recent findings suggests that the LPL rs320 may be func-
tional by altering the binding of a transcription factor
and impacting LPL expression [49]. We found that sed-
entary controls are more likely to have the risk variant
compared with endurance athletes and thus, might in
more risk to develop elevated blood lipids and Cardio
Vascular Disease [55].
A possible explanation to the underrepresentation of
metabolic diseases risk alleles in endurance athletes arising
from studies that evaluated the overall risk of athletes for
metabolic and cardiovascular disease. Guo et al., [56] have
shown that professional strength-oriented athletes at the
heaviest-weight-class are at a significant increased risk for
cardiometabolic disease compared with those at all other
weight categories. Similarly, Urho et al., [57] found that,
compared with controls, strength/power-sports athletes
had a higher risk for high body mass index (BMI), whereas
former endurance athletes had the lowest odds ratios for
T2D and ischemic heart disease. These studies reinforce
our hypothesis that endurance athletes would be at lower
risk for complex metabolic diseases compared to sprint/
power athletes, and controls, and genetics might be, at
least partly, behind these differences.Conclusions
In conclusion, we found a significant association between
IGF2BP2 and LPL SNPs and athletic status in males: en-
durance athletes are less likely to have the metabolic risk
alleles of IGF2BP2 rs4402960 and LPL rs320, compared to
sprint/power athletes and controls. These results suggest
that some SNPs across the human genome have dual ef-
fect and may predispose endurance athletes to reduced
risk of developing metabolic morbidities, whereas sprint/
power athletes might be predisposed to elevated risk.
These results need to be confirmed in athlete cohorts with
different geographical backgrounds. Future studies should
also measure obesity-related intermediate phenotypes,
such as fasting blood glucose levels and plasma lipids that
could lend support for the associations.
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